| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| ARMISTICE CAPITAL, LLC | 5% | $5,365,401 | 1,033,796 | Armistice Capital, LLC | 31 Dec 2024 | |||
| Lynx1 Capital Management LP | 16% | 0% | $3,877,703 | 875,328 | 0% | Lynx1 Capital Management LP | 26 Dec 2025 | |
| Baselake Partners, LP | 9.4% | $2,635,553 | 222,222 | Baselake Partners, LP | 27 Oct 2025 | |||
| Shay Capital LLC | 7.3% | $2,035,520 | 171,629 | Shay Capital LLC | 24 Oct 2025 | |||
| Coastlands Capital LP | 5.1% | $1,423,200 | 120,000 | Coastlands Capital LP | 05 Nov 2025 | |||
| Apeiron Investment Group Ltd. | 4.5% | $376,887 | 72,618 | Apeiron Investment Group Ltd. | 24 Jan 2025 |
As of 30 Sep 2025, 15 institutional investors reported holding 195,338 shares of Neuphoria Therapeutics Inc. - Common Stock, par value $0.00001 per share (NEUP). This represents 3.6% of the company’s total 5,370,110 outstanding shares.
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2025 Q4 | 26,500 | $102,000 | +$102,000 | $3.85 | 1 |
| 2025 Q3 | 195,338 | $2,303,036 | +$535,083 | $11.79 | 15 |
| 2025 Q2 | 177,963 | $1,263,538 | +$105,431 | $7.10 | 9 |
| 2025 Q1 | 163,114 | $935,356 | +$529,238 | $5.76 | 7 |
| 2024 Q4 | 79,719 | $273,435 | +$239,042 | $3.43 | 7 |